These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 11426633)
1. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study . Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S; Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557 [TBL] [Abstract][Full Text] [Related]
3. Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma. Mori M; Niitsu N; Takagi T; Tomiyama J; Matsue T; Nakagawa Y; Okamoto R Leuk Lymphoma; 2001 Apr; 41(3-4):359-66. PubMed ID: 11378549 [TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851. Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653 [TBL] [Abstract][Full Text] [Related]
5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764 [TBL] [Abstract][Full Text] [Related]
6. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385 [TBL] [Abstract][Full Text] [Related]
8. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. Tirelli U; Errante D; Van Glabbeke M; Teodorovic I; Kluin-Nelemans JC; Thomas J; Bron D; Rosti G; Somers R; Zagonel V; Noordijk EM J Clin Oncol; 1998 Jan; 16(1):27-34. PubMed ID: 9440719 [TBL] [Abstract][Full Text] [Related]
9. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895 [TBL] [Abstract][Full Text] [Related]
10. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen. Smalley RV; Weller E; Hawkins MJ; Oken MM; O'Connell MJ; Haase-Statz S; Borden EC Leukemia; 2001 Jul; 15(7):1118-22. PubMed ID: 11455982 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. Miller TP; Dahlberg S; Cassady JR; Adelstein DJ; Spier CM; Grogan TM; LeBlanc M; Carlin S; Chase E; Fisher RI N Engl J Med; 1998 Jul; 339(1):21-6. PubMed ID: 9647875 [TBL] [Abstract][Full Text] [Related]
12. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561 [TBL] [Abstract][Full Text] [Related]
13. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma. Enschede SH; Shahidi H; Venugopal P; Riley MB; Huang R; Jajeh A; Preisler HD; Gregory SA Leuk Lymphoma; 2001 Jan; 40(3-4):325-34. PubMed ID: 11426554 [TBL] [Abstract][Full Text] [Related]
15. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy]. López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196 [TBL] [Abstract][Full Text] [Related]
16. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572 [TBL] [Abstract][Full Text] [Related]
17. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. Gaynor ER; Unger JM; Miller TP; Grogan TM; White LA; Mills GM; Balcerzak SP; Varterasian M; LeBlanc M; Fisher RI J Clin Oncol; 2001 Feb; 19(3):750-5. PubMed ID: 11157027 [TBL] [Abstract][Full Text] [Related]
18. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Ezzat AA; Ibrahim EM; Stuart RK; Ajarim D; Bazarbashi S; El-Foudeh MO; Rahal M; Al-Sayed A; Berry J Med Oncol; 2000 Feb; 17(1):39-46. PubMed ID: 10713659 [TBL] [Abstract][Full Text] [Related]
19. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704 [TBL] [Abstract][Full Text] [Related]